Flag of the European Union EU Clinical Trials Register Help

Clinical trials for psoriasis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    328 result(s) found for: psoriasis. Displaying page 1 of 17.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-004798-17 Sponsor Protocol Number: CAIN457F2301T Start Date*: 2015-05-26
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Evaluation of inflammatory and structural joint damage in patients with psoriasis and psoriatic arthritis treated with secukinumab: A phase 2, single arm, single centre mode of action study (Psoria...
    Medical condition: Psoriasis or prosiatric arthritis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    18.1 10040785 - Skin and subcutaneous tissue disorders 10037154 Psoriasis aggravated LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002588-40 Sponsor Protocol Number: CAIN457ADE02T Start Date*: 2016-05-31
    Sponsor Name:University Hospital Schleswig-Holstein
    Full Title: Exploratory Evaluation of Biomarkers associated with Treatment Response to Cosentyx (Secukinumab) in Psoriasis Patients
    Medical condition: moderate-to-severe psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000253-30 Sponsor Protocol Number: LP0075-34 Start Date*: 2012-11-08
    Sponsor Name:LEO Pharma A/S
    Full Title: An exploratory study evaluating the efficacy of cromoglicate cream compared to cream vehicle in the treatment of itch in psoriasis
    Medical condition: itchy psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003477-36 Sponsor Protocol Number: KKS-303 Start Date*: 2023-06-27
    Sponsor Name:Justus-Liebig University Giessen - KKS Marburg-Giessen
    Full Title: Safety and immunogenicity of SHIngrix VAccination in patients suffering from Psoriasis or Psoriatic arthritis (SHIVAP)
    Medical condition: Psoriasis vulgaris and/or psoriatric arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-002141-39 Sponsor Protocol Number: CDP870-040 Start Date*: 2005-10-25
    Sponsor Name:UCB Pharma S.A.
    Full Title: Multicenter, dose response, randomized, double blin, parallel, 3 arms, placebo controlled clinical trial to evaluate the efficacy and the safety of subcutaneous CDP870 (certolizumab pegol) at 2 dif...
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10037153 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002446-36 Sponsor Protocol Number: BP40635 Start Date*: 2018-11-05
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: AN OPEN LABEL PHASE 2A TRIAL ASSESSING THE CLINICAL EFFICACY AND SAFETY OF RO5459072 IN MODERATE TO SEVERE PSORIASIS
    Medical condition: Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016261-28 Sponsor Protocol Number: H 521 000 - 0915 Start Date*: 2010-01-26
    Sponsor Name:Almirall Hermal GmbH
    Full Title: Randomized, observer-blind, multi-center, reference-controlled phase IIb study to evaluate the efficacy of topically applied LAS41002 lotion in the treatment of scalp psoriasis
    Medical condition: Psoriasis vulgaris on the scalp
    Disease: Version SOC Term Classification Code Term Level
    12.0 10037157 Psoriasis of scalp LLT
    12.0 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002532-24 Sponsor Protocol Number: 0155/2018 Start Date*: 2018-12-27
    Sponsor Name:HELM AG
    Full Title: A phase III, multicentre, randomised, double-blind, parallel-group trial to evaluate the efficacy and safety of a generic gel (calcipotriol + betamethasone 50 μg/g + 0.5 mg/g gel) compared to origi...
    Medical condition: mild to moderate plaque-type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002368-15 Sponsor Protocol Number: PS0016 Start Date*: 2016-11-15
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A Multicenter, Randomized, Subject-Blind, Investigator-Blind Study to Evaluate the Time Course of Pharmacodynamic Response, Safety and Pharmacokinetics of Bimekizumab in Adult Subjects With Moderat...
    Medical condition: Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000462-21 Sponsor Protocol Number: 266-02/06 (AVT-02/2/PSO/02) Start Date*: 2008-01-15
    Sponsor Name:Avontec GmbH
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, intraindividual-comparison phase IIa trial to evaluate the efficacy and safety of 2% AVT-02 UE ointment in the treatment of mild to mode...
    Medical condition: psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002765-31 Sponsor Protocol Number: 066-007/08 (AVT-02/2/PSO/03) Start Date*: 2008-06-18
    Sponsor Name:Avontec GmbH
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, intraindividual-comparison phase IIa trial to evaluate the efficacy and safety of 2% AVT-02 UE ointment in an every other day treatment ...
    Medical condition: psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002317-40 Sponsor Protocol Number: 280210BS Start Date*: 2008-10-17
    Sponsor Name:Perrigo Israel Pharmaceuticals Ltd.
    Full Title: A phase IIa, multi-center, randomized, double-blind, vehicle-controlled study to determine antipsoriatic efficacy and safety of topical CEP-701 (lestaurtinib) cream formulations in patients with ps...
    Medical condition: Chronic plaque type psoriasis of mild to moderate severity, at least one plaque with a treatment area of approximately 25 - 50 cm2
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002998-62 Sponsor Protocol Number: ROF-PSOR_104 Start Date*: 2012-12-13
    Sponsor Name:Takeda Pharma A/S
    Full Title: A Randomized, Single-Center, Observer-Blind, Vehicle- and Active Comparator-Controlled Phase 1b Study to Assess the Effect and Local Safety and Tolerability Of Roflumilast and BYK321084 – Phosphod...
    Medical condition: Mild to moderate, chronical, stable Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    15.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000106-37 Sponsor Protocol Number: 37.07.-92906 Start Date*: 2008-08-28
    Sponsor Name:Klinik für Dermatologie und Allergologie der RUB, St. Josef Hospital
    Full Title: Studies on the combined treatment using etanercept and ultraviolet B for patients with moderate to severe psoriasis vulgaris
    Medical condition: Psoriasis vulgaris (Plaque-Typ)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001126-90 Sponsor Protocol Number: H 1000 2925-06/08 Start Date*: 2006-07-06
    Sponsor Name:Hermal Kurt Herrmann GmbH & Co. OHG
    Full Title: Evaluation of safety and efficacy of Curatoderm® Emulsion in the treatment of patients with mild to moderate plaque psoriasis
    Medical condition: Patients with mild to moderate plaque type Psoriasis vulgaris.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-007037-39 Sponsor Protocol Number: BF-37-CT-002 Start Date*: 2008-02-14
    Sponsor Name:Biofrontera Bioscience GmbH
    Full Title: A Phase II Proof-of-Concept, Randomized, Double-blind, Vehicle-controlled Study, Including an Open-label Comparison to an Active Control, To Assess the Efficacy and Safety/Tolerability of Topical R...
    Medical condition: Patients with stable plaque-type psoriasis with plaques of sufficient size of at least 2 cm in diameter for five comparable treatment areas
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002934-57 Sponsor Protocol Number: PS0018 Start Date*: 2017-02-22
    Sponsor Name:UCB Biopharma SPRL
    Full Title: A multicenter, 48-week, open-label extension study to assess the long-term safety, tolerability, and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis.
    Medical condition: Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-002212-16 Sponsor Protocol Number: CAIN457ADE03 Start Date*: 2015-01-22
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Exploratory study on the kinetics of psoriasis symptoms, pruritus intensity and lesional biomarkers in patients with moderate to severe plaque-type psoriasis treated with subcutaneous secukinumab (...
    Medical condition: chronic moderate to severe plaque type psoriasis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005279-25 Sponsor Protocol Number: LP0058-1072 Start Date*: 2016-06-22
    Sponsor Name:LEO Pharma A/S
    Full Title: LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris A phase 2a proof of concept study comparing an oral tablet formulation of LEO 32731 with a corresponding placebo tablet in pati...
    Medical condition: Psoriasis Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-000197-20 Sponsor Protocol Number: R013 Start Date*: 2008-11-28
    Sponsor Name:Revotar Biopharmaceuticals AG
    Full Title: Multi-center, randomized, double-blind, placebo-controlled Phase 2 study to evaluate the safety and efficacy of Bimosiamose 5% Cream for the treatment of patients with chronic plaque type psoriasis
    Medical condition: chronic plaque-type psoriasis (psoriasis vulgaris)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 06:40:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA